Fungicide Sensitivity of Fusarium oxysporum f. sp. lentis and Fusarium acuminatum Affecting Lentil in the Northern Great Plains

Fusarium oxysporum f. sp. lentis and F. acuminatum cause wilting and root rot in pulse crops including lentil. Fungicide seed treatments are widely used, but information about Fusarium spp. sensitivity in lentils is limited. Here, 30 F. oxysporum f. sp. lentis and 30 F. acuminatum isolates from Montana, southern Canada, North Dakota, and Washington were identified, tested for pathogenicity, and assayed for in vitro sensitivity to pyraclostrobin, prothioconazole, ipconazole, and thiophanate-methyl. F. oxysporum f. sp. lentis and F. acuminatum differed in their sensitivity to all fungicides. No resistant isolates were identified, but F. oxysporum f. sp. lentis had lower EC50 values in pyraclostrobin (averaging 0.47 μg a.i./ml) than F. acuminatum (averaging 0.89 μg a.i./ml) for mycelia assays. Both species had lower EC50 values in prothioconazole, averaging EC50 0.23 in F. oxysporum f. sp. lentis and 0.53 μg a.i./ml in F. acuminatum. F. oxysporum f. sp. lentis isolates had the lowest EC50 values on ipconazole compared to F. acuminatum (0.78 and 1.49 μg a.i./ml). The pathogens were least sensitive to thiophanate-methyl (1.74 μg a.i./ml for F. oxysporum f. sp. lentis and 1.91 μg a.i./ml for F. acuminatum). Overall sensitivity to the fungicides was higher in F. oxysporum f. sp. lentis than F. acuminatum. This study provides reference EC50 values while pointing to the possibility of differential fungicide efficacies on Fusarium spp. This will be helpful to monitor shifts in sensitivity of Fusarium spp. and devise robust root rot/wilt management approaches.

Evaluation of Seed Transmission Rates of Wheat Streak Mosaic Virus in Mechanically Inoculated Winter and Spring Wheat Cultivars in Montana

Wheat streak mosaic disease is caused by wheat streak mosaic virus (WSMV) and two other viruses and persistently limits wheat yields in the Great Plains region of the United States. Seed transmission of viruses is an important consideration in international movement and is important epidemiologically. Seed transmission of WSMV in wheat was first reported from Australia in 2005, but there is little data from United States cultivars on the rate of seed transmission. In 2018, mechanically inoculated winter and spring wheat cultivars were evaluated in Montana. We found differences in WSMV seed transmission rates between winter and spring wheat, with average transmission rates in spring wheat (3.1%) being five times higher compared to winter wheat (0.6%). Seed transmission rates in spring wheat were twice as high as the highest previously reported transmission rate for individual genotypes, 1.5%. The results from this study provide a strong argument for increasing the current testing of seed for breeding purposes prior to international movement when WSMV has been observed and caution against using grain from WSMV-infected fields as seed source because it can heighten the risk of wheat streak mosaic outbreaks.

Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors

The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%. Small retrospective studies suggest that O(6)-methylguanine DNA methyltransferase (MGMT) deficiency predicts response to temozolomide. High tumor proliferative activity is also commonly perceived as a significant predictor of response to cytotoxic chemotherapy. It is unclear whether chromosomal instability (CIN), which correlates with alternative lengthening of telomeres (ALT), is a predictive factor. In this study, we evaluated 143 patients with advanced pNET who underwent treatment with CAPTEM for radiographic and biochemical response. MGMT expression (n=52), grade (n=128) and ALT activation (n=46) were investigated as potential predictive biomarkers. Treatment with CAPTEM was associated with an overall response rate (ORR) of 54% by RECIST 1.1. Response to CAPTEM was not influenced by MGMT expression, proliferative activity or ALT pathway activation. Based on these results, no biomarker-driven selection criteria for use of the CAPTEM regimen can be recommended at this time.